AUA Annual Meeting Expected Draw Some 16,000 Attendees
Researchers are scheduled to present more than 2500 studies at the American Urological Association 2018 annual meeting in San Francisco.
Diagnosis & Disease Information
Medical Expulsive Therapy Fails to Improve Ureteral Stone Passage
In a large study, tamsulosin use was not associated with a significant improvement in spontaneous stone passage rates compared with placebo among patients with acute ureteric colic.
Adjuvant RT Plus ADT Beneficial in Selected Prostate Cancer Cases
Study identifies which PCa patients with positive lymph nodes may have improved survival with the addition of adjuvant radiotherapy to androgen-deprivation therapy.
Biopsy-to-RP Delay May Up Prostate Cancer Recurrence Risk
Researchers concluded that a greater than 90-day interval from prostate biopsy to radical prostatectomy increases the risk of biochemical recurrence among men with Gleason 3+4 disease.
Metastatic Prostate Cancer at Diagnosis in Decline
Study documents a drop in the incidence of de novo metastatic PCa from 1980 to 2011 in the United States.
First-line Pazopanib May Improve Outcomes in Advanced RCC
Treatment-naïve patients with advanced clear-cell renal cell carcinoma had significantly longer progression-free survival when treated with pazopanib instead of temsirolimus.
Upfront Docetaxel May Have Role in Advanced Prostate Cancer
Added to hormone therapy, docetaxel offers a cost effective way to prolong hormone-sensitive disease and improve quality of life years, especially among men with non-metastatic disease, study finds.
Non-urothelial Bladder Cancer Type Affects Disease-Specific Survival
Patients with bladder adenocarcinomas have the best survival, whereas those with small cell carcinomas of the bladder have the worst.
Metastatic RCC Treatment With Nivolumab Confirmed Safe, Efficacious
The safety and efficacy of nivolumab for treating metastatic renal cell carcinoma is comparable to that found in the CheckMate 025 trial.
Axitinib-Pembrolizumab Combo Promising for Advanced RCC
In a phase Ib study, dual therapy with axitinib and pembrolizumab was well tolerated and demonstrated antitumor activity in treatment-naïve patients with advanced renal cell carcinoma.
- Loading...
Loading...
Next post in Genitourinary Cancers Symposium
Loading... 
Loading...